Flare Phenomenon After 177Lu-DOTA-IBA Therapy in Bone Metastases of Lung Cancer

被引：2

作者：

Hua, Qingchu ^{[1
,2
,3
]}

Wang, Wei ^{[1
,2
,3
]}

Qu, Gengcuo ^{[1
,2
,3
]}

Pei, Wenjie ^{[1
,2
,3
]}

Chen, Yue ^{[1
,2
,3
]}

机构：

[1] Southwest Med Univ, Dept Nucl Med, Affiliated Hosp, 25 TaiPing St, Luzhou 646000, Sichuan, Peoples R China

[2] Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou, Sichuan, Peoples R China

[3] Southwest Med Univ, Inst Nucl Med, Luzhou, Sichuan, Peoples R China

来源：

CLINICAL NUCLEAR MEDICINE | 2024年 / 49卷 / 08期

关键词：

flare phenomenon; Lu-177; DOTA-IBA; bone metastases; lung cancer; bone pain;

D O I：

10.1097/RLU.0000000000005303

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The flare phenomenon is a transient increase in the number or intensity of lesions on bone scans after treatment, signifying curative effect. DOTA-ibandronic acid (DOTA-IBA) is a new prodrug that targets bone metastases and can be labeled with Lu-177. Here, we report the case of a 58-year-old woman with bone metastasis, in whom the flare phenomenon was observed after 4 cycles of Lu-177-DOTA-IBA treatment. No adverse effects were observed during the treatment and follow-up periods.

引用

页码：793 / 796

页数：4

共 50 条

[1] 177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases
Li, Hongmei
Xu, Tingting
Hua, Qingchu
Wang, Li
Chen, Yue
CLINICAL NUCLEAR MEDICINE, 2023, 48 (08) : 740 - 742
[2] Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
Li, Hongmei
Pei, Wenjie
Yang, Xiqun
Qu, Gengcuo
Hua, Qingchu
Liu, Lin
Wang, Yudi
Xu, Tingting
Chen, Yue
EJNMMI RESEARCH, 2024, 14 (01)
[3] Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
Hongmei Li
Wenjie Pei
Xiqun Yang
Gengcuo Qu
Qingchu Hua
Lin Liu
Yudi Wang
Tingting Xu
Yue Chen
EJNMMI Research, 14
[4] Treatment of Bone Metastases of Breast Cancer With 177Lu-DOTA-IBA
Deng, Jia
Yang, Jian
Cheng, Zixuan
Chen, Yue
CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : 659 - 661
[5] Efficacy and Safety of 177Lu-DOTA-IBA in Tumor Bone Metastasis Treatment A Prospective Clinical Trial
Xu, Tingting
Wang, Yudi
Liu, Guangfu
Li, Hongmei
Qu, Gengcuo
Zhang, Xiaoling
Wang, Wei
Xing, Naiguo
Hua, Qingchu
Chen, Yue
CLINICAL NUCLEAR MEDICINE, 2025, 50 (02) : 119 - 124
[6] Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases
Fernandez, Rene
Eppard, Elisabeth
Lehnert, Wencke
Jimenez-Franco, Luis David
Soza-Ried, Cristian
Ceballos, Matias
Ribbeck, Jessica
Kluge, Andreas
Roesch, Frank
Meckel, Marian
Zhernosekov, Konstantin
Kramer, Vasko
Amaral, Horacio
JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (08) : 1126 - 1132
[7] Response and long-term control of bone metastases after peptide receptor radionuclide therapy with Lu177-DOTA octreotate
Ezziddin, Samer
Sabet, Amir
Heinemann, Florian
Yong-Hing, Charlotte
Ahmadzadehfar, Hojjat
Guhlke, Stefan
Hoeller, Tobias
Willinek, Winfried
Biersack, Hans
JOURNAL OF NUCLEAR MEDICINE, 2011, 52
[8] 177Lu-DOTA-Nimotuzumab: a new potential agent for cancer therapy
Calzada, Victoria
Garcia, Maria F.
Camacho, Ximena
Fernandez, Marcelo
Gambini, Juan P.
Zhang Xiuli
Diaz-Miqueli, Arlhee
Iznaga-Escobar, Normando
Baiter, Henia
Deutscher, Susan
Quinn, Thomas P.
Cabral, Pablo
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 : S564 - S564
[9] Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases A Phase 0/I Study
Qiu, Lin
Wang, Yingwei
Liu, Hanxiang
Wang, Qixin
Chen, Lin
Liu, Lin
Wang, Li
Feng, Yue
Chen, Yue
CLINICAL NUCLEAR MEDICINE, 2023, 48 (06) : 489 - 496
[10] Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model
Schmitt, A
Bernhardt, P
Nilsson, O
Ahlman, H
Kölby, L
Maecke, HR
Forssell-Aronsson, E
JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (09) : 1542 - 1548

← 1 2 3 4 5 →